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Introduction: The aim of this study was to determine and evaluate
the recommended dose of docetaxel in combination with a novel
oral 5-fluorouracil analogue S-1 and evaluate the efficacy and safety
in patients with previously treated non-small cell lung cancer.
Methods: In phase I, patients with previously treated non-small cell
lung cancer were treated with docetaxel (starting dose 40 mg/m2)
intravenously on day 1 and oral administration of S-1 at a fixed dose
of 80 mg/m2 on days 1 to14 every 3 weeks. The recommended dose
was the dose level preceding the maximum tolerated dose; once
determined, patients were enrolled in phase II.
Results: The recommended dose of docetaxel was 40 mg/m2 in
combination with S-1 80 mg/m2/d. Of 30 patients enrolled in phase
II part, 29 patients were eligible and analyzed. No complete re-
sponse and 7 (24.1%) partial responses were observed, for an overall
response rate of 24.1% (95% confidence interval, 10.3–43.5%).
Median overall survival was 11.8 months. The 1-year survival rate
was 42%. The grade 3 to 4 hematologic toxicities were neutropenia
(34.5%), leukopenia (20.6%), and anemia (10.3%). The grade 3 to 4
nonhematological toxicities included fever 2 (6.9%), diarrhea 1
(3.4%), stomatitis 1 (3.4%), cerebral infarction 1 (3.4%), and pneu-
monitis 1 (3.4%). There was one treatment-related death due to
relapse of drug induced pneumonitis.
Conclusions: This combination chemotherapy is highly active and
well tolerated in previously treated patients with non-small cell lung
cancer. These results are encouraging and warrant additional inves-
tigation.
Key Words: Phase I/II, Non-small cell lung cancer, Second-line
chemotherapy, S-1, Docetaxel.
(J Thorac Oncol. 2008;3: 1012–1017)
Lung cancer is the leading cause of tumor-related deathworldwide. Non-small cell lung cancer (NSCLC) accounts
for approximately 80% of all lung cancers, and by 2002, there
were 1.35 million new cases, representing 12.4% of all new
cancers.1 Surgery offers the best chance for cure in stage I
and II NSCLC. However, most patients with NSCLC have
advanced disease at diagnosis. Chemotherapy is the mainstay
of management. The American Society of Clinical Oncolo-
gy’s clinical guidelines recognize that chemotherapy can
prolong the survival of advanced NSCLC and is appropriate
for those with good PS.2 The use of doublet regimens has
been widely adopted. The principal agents are platinum
analogs, taxanes, gemcitabine, irinotecan, and vinorelbine.3,4
First-line platinum-based chemotherapy is somewhat effec-
tive. However, all patients with advanced NSCLC will ulti-
mately progress or relapse. Therefore, second-line chemo-
therapy is of importance in the clinical management of the
patients who had previously received chemotherapy.
Docetaxel has been proven to show antitumor activity
against various cancers, including NSCLC.5–8 This antican-
cer agent is a mitotic spindle poison that promotes tubulin
polymerization and inhibits the depolymerization of micro-
tubules.9 Docetaxel is one of the standard drugs in second-
line chemotherapy. Two recent studies showed improved
survival in patients with NSCLC previously treated with
platinum in comparison to best supportive care or other
drugs.10,11
S-1 is a new oral fluorinated pyrimidine. It is a combi-
nation drug consisting of a mixture of futraful, 5-chloro-2,4-
dihydrozypyridine, and potassium oxonate (Oxo) in a molar
ratio of futraful: 5-chloro-2,4-dihydrozypyridine: Oxo  1:
0.4: 1, based on the biochemical modulation of 5-FU.12 In
phase II studies for advanced NSCLC conducted in Japan,
favorable results of S-1 monotherapy or combination therapy
have been reported. Kawahara et al. reported that S-1 mono-
therapy achieved an overall response rate of 22.0% and a
median survival time (MST) of 10.2 months.13 There were no
irreversible, severe or unexpected toxicities. Ichinose et al.
reported that S-1 plus cisplatin achieved a 47% response rate
and a MST of 11 months.14 Docetaxel and S-1 have shown
synergy in human gastric, and breast cancer xenograft mod-
els.15,16 The expression of thymidylate synthase and dihy-
drouracil dehydrogenase was lower than compared with con-
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trol levels. In in vivo experiments using breast cancer
xenografts, significant down-regulation of dihydrouracil de-
hydrogenase activity was observed in tumors treated with
S-1, docetaxel and their combination.16 However, thymidy-
late synthase activity was not significantly different from
control. We hypothesized that the doublet combination che-
motherapy using docetaxel and S-1 would have more effect
against NSCLC as compared with the monotherapy of do-
cetaxel. The rationale for this combination is that the drugs
have different action mechanisms and safety profiles. To
improve upon the efficacy of docetaxel alone as second-line
treatment, we conducted a phase I/II study of doublet che-
motherapy of docetaxel plus S-1.
PATIENTS AND METHODS
Eligibility
Eligible patients were required to have locally ad-
vanced or metastatic NSCLC and had failed one or more prior
chemotherapy regimens and had at least one measurable
lesion. Other main eligibility criteria were as follows: age 20
years or more; Eastern Cooperative Oncology Group perfor-
mance status (PS) 0 or 1; estimated life expectancy 3
months; one or more prior chemotherapy regimens that did
not include docetaxel or 5-FU and that was completed 4
weeks before entry; adequate bone marrow, hepatic, renal,
and cardiac function [i.e., WBC count 4000/l, absolute
neutrophil count 2000/l, platelet count 100,000/l, he-
moglobin 9.5 g/dl, serum bilirubine level 1.5 mg/dl,
aspartate aminotransferase, and alanine aminotransferase
within 2.5 times the upper limit of normal (ULN) for the
institution, blood urea nitrogen 25 mg/dl, serum creatinine
within the ULN, and creatinine clearance 60 ml/min].
Exclusion criteria included the presence of other concomitant
or metachronous cancers, severe allergy to drugs, simultaneous
infectious disease, interstitial pneumonia, or other serious under-
ling medical conditions. The study was approved by the insti-
tutional review board of the participating center and all patients
provided written informed consent.
Evaluation
All eligible patients who received any part of the
treatment were considered assessable for response and toxic-
ity. The complete blood cell counts and blood chemistry
studies were measured weekly. The response was assessed
based on weekly chest radiograph or computed tomography
scan every 4 weeks findings that initially had been used to
define tumor extent during the treatment period. The response
was evaluated according to the criteria of response evaluation
criteria in solid tumors. A complete response (CR) was
defined as the complete disappearance of all clinically detect-
able tumors for at least 4 weeks. A partial response (PR) was
defined as an at least 30% decrease in the sum of the longest
diameters of the target lesions for more than 4 weeks with no
new area of malignant disease. Progressive disease (PD)
indicated at least a 20% increase in sum of the longest
diameter of the target lesions or a new malignant lesion.
Stable disease (SD) was defined as insufficient shrinkage to
qualify for PR and insufficient increase to qualify for PD. The
best response achieved during the treatment course was
reported. Toxicity was graded according to the National
Cancer Institute Common Toxicity Criteria version 2.0.17
Study Design and Treatment Schedule
This was an open-label multicenter, single-arm phase
I/II study in patients with previously treated NSCLC. The
objective of the phase I part was to determine the dose-
limiting toxicity (DLT), maximum-tolerated dose (MTD),
and recommended dose (RD) of docetaxel plus a fixed dose
of S-1. In the phase II part, the primary objective was to
estimate the overall response rate of this combination at the
RD. Secondary objectives were to assess overall survival,
1-year survival rate, adverse events, and progression-free
survival (PFS).
In the phase I part of this study, patients received
variable doses of docetaxel administered as a 1-hour infusion
on day 1 and oral S-1 administered at a fixed dose of 80 mg/m
on days 1 to 14 every 3 weeks. S-1 is only available in 20-mg
or 25-mg capsules. Therefore, it is easier to plan the dose
escalation procedure or a dosage adjustment of docetaxl than
S-1. The initial starting dose of docetaxel was 40 mg/m2
(dose level 1), and step-wise dose increases to 50 (dose level
2) and 60 mg/m2 (dose level 3) were planned for successive
patient cohorts. DLT was determined during the first treat-
ment cycle. At least three patients were enrolled at each dose
level: (i) the dose was defined as MTD when two or more of
three patients developed DLT; (ii) when one of three patients
developed DLT, three other patients were enrolled; (iii) when
three or more of six patients developed DLT, the dose was
defined as MTD; (iv) when one or two of six patients
developed DLT, the dose was increased to the next level.
DLT was defined as follows: grade 4 neutropenia;
grade 3 or 4 neutropenia associated with a fever 38°C;
grade 4 thrombocytopenia; or grade 3 or 4 nonhematological
toxicities. A DLT was also reported if 7 days or more
omission of S-1, or if the second cycle was delayed until after
day 29 because the dosing requirements were not satisfied.
S-1 80 mg/m2 per day was given orally in 2 divided
dose after a meal for 2 weeks, after a drug-free interval of 1
week (one cycle). Three doses of S-1 were selected according
to body surface area (BSA). So that they would be approxi-
mately equivalent to 80 mg/m2: BSA1.25 m2, 40 mg b.i.d.;
BSA 1.25, but 1.5 m2, 50 mg b.i.d.; and BSA 1.5 m2, 60
mg b.i.d. Docetaxel 40 mg/m2 was diluted in 500 ml of 0.9%
salaine and administered as a 1-hour infusion on the morning
of day 1 of each cycle (i.e., every 3 weeks). Dexamethasone
8 mg was infused 1 hour before docetaxel administration.
Granulocyte colony-stimulating factor was permitted if a
patient developed grade 4 neutropenia; primary prophy-
laxis was not allowed. Antiemetic (ondansetron) treatment
was allowed at the discretion of the treatment physician.
In the phase II part of this study, patients received the
RD of docetaxel on day 1 and oral S-1 80 mg/m2 in accor-
dance with the treatment schedule described above. The
treatment was repeated every 21 days for at least two cycles
unless there was disease progression, unacceptable toxicity,
patient refusal, or the physician’s decision to stop treatment.
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S-1 was stopped if there was a leukocyte count of 2000/l,
neutrophil count of 1000/l, platelet count of 50,000/l,
and a grade 3 or 4 nonhematological toxicity.
The next course of treatment was initiated only when
the neutrophil count recovered to 2000/l, platelet count to
100,000/l, creatinine within the ULN, total bilirubin1.5
mg/dl, and the level of aspartate aminotransferase/alanine
aminotransferase became2.5 times the ULN. If patients did
not recover from these toxicities within 2 weeks of the last
administration of S-1, they were withdrawn from this study.
If patients experienced grade 4 neutropenia, fever 38.0°C
with grade 3 to 4 neutropenia, grade 3 or more thrombocy-
topenia, the dose of docetaxel was reduced by 10 mg/m2 in
the subsequent cycle. The dose of S-1 was to be reduced by
20 or 30 mg per day if any grade 3 or 4 nonhematological
toxicity was recognized including nausea/vomiting, anorexia,
and general fatigue.
Statistical Analysis
Based on the assumption that a response rate of higher
than 20% would warrant a further investigation of this com-
bination chemotherapy, and a rate of below 5% would make
such an investigation unnecessary, a sample size of 27 pa-
tients was required with an alpha error of 0.05 and a beta error
of 0.2. Therefore, the accrual of 30 patients was planned for
a 2-year period since we considered that several ineligible
patients might be identified in the course of the study. PFS
was defined as the interval from the start of the treatment to
the diagnosis of progression or death from any cause. Overall
survival was defined as the interval between when treatment
was started and death or the final follow-up visit. Median
overall survival and median PFS were estimated by the
Kaplan-Meier method.18 Survival time was recorded at the
last confirmation date if the patients were alive.
RESULTS
Between January 2005 and May 2006, 33 patients were
enrolled on this study. Nine patients (6 in level 1 and 3 in
level 2) were enrolled into the phase I part. Of 30 patients
enrolled into the phase II part of the study, one patient did not
receive either docetaxel or S-1 because his disease had
progressed rapidly. This patient was excluded from all anal-
yses. Twenty-nine patients who were given the RD were
evaluated for efficacy and detailed safety profile: these pa-
tients consisted of 6 and 23 patients who entered into the
study at phase I and II, respectively.
Phase I
The first cohort of 6 patients received docetaxel 40
mg/m2 plus S-1 80 mg/m2 (dose level 1). Among these
patients, one experienced cerebral infarction (grade 4 CNS
cerebrovascular ischemia). No other DLT was observed at
dose level 1. At dose level 2 (docetaxel 50 mg/m2), 2 of the
3 patients developed grade 4 neutropenia which was consid-
ered DLT. From these results, the MTD and RD were
determined to be level 2 and level 1, respectively.
Phase II
Baseline characteristics of the 29 patients treated at the
RD are shown in Table 1. Ages ranged from 48 to 79 years,
with a median of 67 years. There were 23 men and 6 women.
Nine patients had Eastern Cooperative Oncology Group PS 0,
20 patients had PS 1. Seven patients had clinical stage IIIB
disease and 22 had stage IV disease. Histology consisted of
adenocarcinoma in 16 patients, squamous cell carcinoma in
10, large-cell carcinoma in 2, and other in one. A single prior
chemotherapy regimen had been given in 23 patients, 2
regimen in 4 patients and 3 in 2 patients. Twenty-eight
(96.5%) patients had received a platinum-based chemo-
therapy.
Response and Survival
Of 29 patients assessable for response, none of the
patients achieved a CR; 7 (24.1%) achieved a PR with an
overall response rate of 24.1% [95% confidence interval
(95% CI), 10.3–44.8%]. Thirteen (44.8%) had SD and 7
patients (24.1%) had PD as best response. Two were uneva-
luable. The tumor control rate (CR  PRSD) was 68.9%
(95% CI, 49.2–84.7%). Among all 29 patients, the median
PFS was 3.9 months. As shown in Figure 1, the MST of all
patients was 11.8 months, and the 1-year survival rate was
41.8% (95% CI, 21.8–61.8%).
Toxicity of Treatment
Hematological toxicity and nonhematological toxicity
were analyzed during treatment and the follow-up period.
The major toxicities during the study period are shown in
Tables 2 and 3. The grade 3 to 4 hematological toxicities
were neutropenia (34.5%), leukopenia (20.6%), and anemia
(10.3%). None of the patients developed grade 2 or more
thrombocytopenia. The grade 3 to 4 nonhematological toxic-
ities included fever 2 (6.9%), diarrhea 1 (3.4%), stomatitis 1
(3.4%), cerebral infarction 1 (3.4%), and pneumonitis 1
(3.4%). There was one treatment-related death. The patient
died 54 days after the first cycle of chemotherapy due to
relapse of drug induced pneumonitis.
Treatment Delivery
The median number of cycles administered was 3
(range, 1–8 cycles).
TABLE 1. Patients’ Characteristics
No. patients 30
Eligible 29
Male/Female 23/6
Median age, in yr (range) 67 (48–79)
PS 0/1 9/20
ad/sq/la/other 16/10/2/1
Stage IIIb/IV 7/22
No. previous chemo regimens
1/2/3 23/4/2
RT 13
Operation 3
PS, performance status; Chemo, chemotherapy; RT, radiotherapy.
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In all, 20 (62.5%) patients received at least 2 cycles of
treatment. The reasons for terminating the chemotherapy
before the second treatment cycle were disease progression in
seven patients and adverse events in two patients. Five
patients each required dose reductions of docetaxel or S-1,
respectively.
Poststudy Therapy
Eighteen patients received at least one form of antitu-
moral treatment after disease progression. Thirteen patients
received chemotherapy alone, the most frequently prescribed
treatment was carboplatin plus gemcitabine. Ten patients
received gefitinib.
DISCUSSION
The benefit of second-line chemotherapy has been sub-
stantiated by randomized trials using docetaxel, pemetrexed,
topotecan, and erlotinib.10,11,19–21 The response rate was re-
ported to be 6.7 to 10.8% for docetaxel, 9.1% for pemetrexed,
5% for topotecan, and 8.9% for erlotinib. The 1-year survival
rate of these reports ranges from 25 to 37%. It is clear that
there is an urgent need for more active treatment regimens to
patients with relapsed or refractory NSCLC. On the other
hand, second-line chemotherapy is a palliative treatment.
Therefore, pretreated patients have poorer tolerance to sec-
ond-line chemotherapy, lower toxicity, and efficacy, which is
important when considering the second-line chemotherapy.
To improve the efficacy of second-line chemotherapy, a
number of studies have conducted two-drug second-line ther-
apy combinations.22–25 Georgoulias et al. reported a random-
ized phase II study that compared single agent irinotecan with
a combination of irinotecan plus gemcitabine.24 Their results
failed to demonstrate a statistically significant survival ad-
vantage of the combination of irinotecan and gemcitabine
over irinotecan alone, although the combination regimen was
better in terms of response rate and QOL. A phase III study
by Takeda et al. comparing docetaxel alone versus docetaxel
plus gemcitabine was terminated early with unexpected inci-
dence of interstitial lung disease and treatment-related deaths
due to interstitial lung disease, only in the combination
chemotherapy group.25 Indeed, a comparison of combination
chemotherapy versus monotherapy in patients with previ-
ously treated NSCLC failed to demonstrate any difference in
terms of overall survival. For the moment, single-agent ther-
apy remains the standard option for patients with relapsed or
refractory NSCLC.
In the present study, we administered S-1 plus do-
cetaxel to previously treated patients with NSCLC. Seven of
the 29 patients (24.1%) achieved a PR as a result. The MST
of this regimen was 11.8 months and the 1-year survival rate
was 41.8% (Figure 1). The results of the present study are
promising, suggesting that the survival of patients treated
FIGURE 1. Overall survival curve.
TABLE 2. Hematological Toxicity
Grade
Toxicity 1 2 3 4
Leukopenia 3 8 6 0
Neutropenia 1 5 7 3
Thrombocytopenia 2 0 0 0
Hemoglobin 7 7 3 0
TABLE 3. Nonhematological Toxicity
Grade
Toxicity 1 2 3 4
Nausea 5 0 0 0
Vomiting 1 2 0 0
Fatigue 1 5 0 0
Infection 0 0 0 0
Fever 3 0 2 0
Diarrhea 4 0 1 0
Ulcer 0 1 0 0
Cerebrovascular ischemia 0 0 0 1
Skin 2 3 0 0
Stomatitis 3 0 1 0
Pneumonitis 1 0 0 1*
*One patient died from relapse of drug induced pneumonitis.
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with combination therapy could be improved compared with
the survival of those treated with docetaxel alone as a second-
line treatment. However, we can not exclude the possibility
that the poststudy treatment such as gefitinib or selection bias
might also have played a role in prolonging the survival
times. Various combination chemotherapy regimens includ-
ing oral fluoropyrimidine, such as UFUR and capecitabine,
have been investigated in NSCLC.26–28 Kindwall-Keller et al.
reported a phase II study of docetaxel and capecitabine in
previously treated patients with NSCLC.27 The response rate
was 26% with the MST and 1-year survival rate of 9.1 month
and 37%. Chen et al. used UFUR with gemcitabine for 45
patients who failed previous platinum-based chemotherapy.28
Their patients were treated with 1000 mg/m2 gemcitabine on
days 1 and 8, plus oral UFUR 200 mg/m2/d from days 1 to 14
of every 3 weeks. They reported that 7 patients (15.6%) had
a PR. The MST was 13.2 months.
Our study used 40 mg/m2 of docetaxel every 3 weeks is
lower than that commonly using docetaxel alone at the dose
of 75 mg/m2 as second-line setting in the United States and
Europe. By combining docetaxel at 40 mg/m2 on day 1 with
S-1 at 80 mg/m2/d on days 1 to 14 every 3 weeks, we
expected less toxicity, with preserved efficacy. In Japan,
docetaxel 60 mg/m2 every 3 weeks is the commonly used
dose. In a phase I study of docetaxel plus S-1, the RD of
docetaxel was determined to be 40 mg/m2 in combination
with S-1 80 mg/m2/d on days 1 to 14. This combination
chemotherapy has been evaluated in gastric cancer in Ja-
pan.29–31 The RD of docetaxel was 40 mg/m2 in combination
with S-1 80 mg/m2/d in the gastric cancer which was the
same is our study as a second-line setting. Yamaguchi et al.
speculate that the reason for the lower dose of docetaxel may
be that the pharmacokinetic parameters (AUC and Cmax) of
5-FU increase according to the dose of docetaxel.31
In our study, the main toxicity was myelosuppression.
The most common hematological toxicities were neutropenia
and leukopenia. Grade 3 or 4 neutropenia occurred in 34.5%
and grade 3 or 4 anemia occurred in 10.3%. In phase III
studies of docetaxel 75 mg/m2 given as a single agent, grade
3 or 4 neutropenia occurred in 40.2 to 67.3% and grade 3 or
4 anemia occurred in 4.3 to 10%.10,19,20 It seemed that the
incidence of grade 3 or 4 neutropenia were lower in our study
than in those phase III studies. The majority of nonhemato-
logical toxicities were relatively mild. However, grade 4
cerebral infarction and pneumonitis were observed. It is
unclear whether this adverse CNS event was related to this
combination chemotherapy. This may be due to the hyperco-
agulability associated with lung cancer. Clotting activation
and thromboembolic manifestations are common features in
patients with cancer. Therefore, this CNS event might have
occurred by chance.32
In conclusion, our study indicates that the combination
of docetaxel pulse S-1 is an effective and well-tolerated
regimen for the treatment of patients with previously treated
NSCLC. This regimen seems suitable as a second-line treat-
ment for patients with NSCLC. The response rate and median
survival are encouraging and warrant additional investigation.
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